Table 2 Selected concomitant medication use among elderly subjects during the CONFIRMS trial
From: The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Febuxostat 40 mg N = 115 | Febuxostat 80 mg N = 128 | Allopurinol 200/300 mg N = 131 | |
|---|---|---|---|
n (%) | |||
Subjects with one or more concomitant medication | |||
Agents acting on the renin-angiotensin systema | 65 (57) | 78 (61) | 83 (63) |
Analgesics | 23 (20) | 33 (26) | 27 (21) |
Antiinflammatory and antirheumatic products | 26 (23) | 32 (25) | 26 (20) |
Antithrombotic agents | 58 (50) | 65 (51) | 65 (50) |
Beta blockers | 45 (39) | 43 (34) | 55 (42) |
Calcium channel blockers | 19 (17) | 21 (16) | 30 (23) |
Corticosteroids for systemic use | 12 (10) | 21 (16) | 15 (11) |
Drugs for acid-related gastrointestinal disorders | 23 (20) | 32 (25) | 34 (26) |
Drugs used in diabetes | 20 (17) | 25 (20) | 29 (22) |
Diuretics | 26 (23) | 32 (25) | 33 (25) |
Lipid modifying agents | 64 (56) | 69 (54) | 75 (57) |
Other antihypertensivesb | 13 (11) | 4 (3) | 10 (8) |